Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis

Lancet

Volumn 368, Issue 9533, 2006, Pages 371-378

  McRae, Simon ^a,b   Tran, Huyen ^b   Schulman, Sam ^c   Ginsberg, Jeff ^b   Kearon, Clive ^d  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^c HAMILTON HEALTH SCIENCES   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ESTROGEN; ORAL CONTRACEPTIVE AGENT;

ANTICOAGULANT THERAPY; ARTICLE; CLINICAL TRIAL; COCHRANE LIBRARY; COHORT ANALYSIS; CONFIDENCE INTERVAL; EMBASE; ESTROGEN THERAPY; FOLLOW UP; HIGH RISK POPULATION; HUMAN; LONG TERM CARE; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; PREGNANCY; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; RISK FACTOR; SEX DIFFERENCE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 33746298920     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)69110-1     Document Type: Article

References (34)

1. White R. The epidemiology of venous thromboembolism. Circulation 107 suppl 1 (2003) I4-I8
2. Prandoni P., Lensing A., Cogo A., et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 125 (1996) 1-7
3. Hansson P., Sorbo J., and Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 160 (2000) 769-774
4. Douketis J., Kearon C., Bates S., Duku E., and Ginsberg J. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 279 (1998) 458-462
5. Kahn S., and Ginsberg J. The post-thrombotic syndrome: current knowledge, controversies, and directions for future research. Blood Rev 16 (2002) 155-165
6. Pengo V., Lensing A., Prins M., et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 350 (2004) 2257-2264
7. Kearon C., Gent M., Hirsh J., et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 340 (1999) 901-907
8. Schulman S., Granqvist S., Holmstrom M., et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 336 (1997) 393-398
9. Ost D., Tepper J., Mihara H., Lander O., Heinzer R., and Fein A. Duration of anticoagulation following venous thromboembolism: a meta-analysis. JAMA 294 (2005) 706-715
10. Linkins L., Choi P., and Douketis J. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 139 (2003) 893-900
11. Research Committee of the British Throacic Society. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Research Committee of the British Thoracic Society. Lancet 340 (1992) 873-876
12. Schulman S., Rhedin A., Lindmarker P., et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 332 (1995) 1661-1665
13. Levine M., Hirsh J., Gent M., et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 74 (1995) 606-611
14. Palareti G., Legnani C., Cosmi B., Guazzaloca G., Pancani C., and Coccheri S. Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped. Thromb Haemost 87 (2002) 7-12
15. Baglin T., Luddington R., Brown K., and Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 362 (2003) 523-526
16. Heit J., Mohr D., Silverstein M., Petterson T., O'Fallon W., and Melton L. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 160 (2000) 761-768
17. Schulman S., Wahlander K., Lundstrom T., Clason S., and Eriksson H. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 349 (2003) 1713-1721
18. Prandoni P., Lensing A., Piccioli A., et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100 (2002) 3484-3488
19. Kyrle P., Minar E., Bialonczyk C., Hirschl M., Weltermann A., and Eichinger S. The risk of recurrent venous thromboembolism in men and women. N Engl J Med 350 (2004) 2558-2563
20. Baglin T., Luddington R., Brown K., and Baglin C. High risk of recurrent venous thromboembolism in men. J Thromb Haemost 2 (2004) 2152-2155
21. Agnelli G., Becattini C., and Prandoni P. Recurrent venous thromboembolism in men and women. N Engl J Med 351 (2004) 2015-2018
22. The Evidence-Based Medicine Working Group. Users' guides to the medical literature: a manual for evidence-based clinical practice (2002), AMA press, Chicago
23. DerSimonian R., and Laird N. Meta-analysis in clinical trials. Control Clin Trials 7 (1986) 177-188
24. Franzeck U., Schalch I., Jager K., Schneider E., Grimm J., and Bollinger A. Prospective 12-year follow-up study of clinical and hemodynamic sequelae after deep vein thrombosis in low-risk patients (Zurich study). Circulation 93 (1996) 74-79
25. AbuRahma A., Stickler D., and Robinson P. A prospective controlled study of the efficacy of short-term anticoagulation therapy in patients with deep vein thrombosis of the lower extremity. J Vasc Surg 28 (1998) 630-637
26. Piovella F., Crippa L., Barone M., et al. Normalization rates of compression ultrasonography in patients with a first episode of deep vein thrombosis of the lower limbs: association with recurrence and new thrombosis. Haematologica 87 (2002) 515-522
27. Palareti G., Legnani C., Cosmi B., et al. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation 108 (2003) 313-318
28. Ridker P., Goldhaber S., Danielson E., et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 348 (2003) 1425-1434
29. Kearon C., Ginsberg J., Anderson D., et al. Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. J Thromb Haemost 2 (2004) 743-749
30. Poli D., Antonucci E., Cecchi E., et al. Clotting activation after oral anticoagulant therapy discontinuation: a risk factor for recurrent venous thromboembolism. Blood Coagul Fibrinolysis 15 (2004) 221-225
31. Lagerstedt C., Olsson C., Fagher B., Oqvist B., and Albrechtsson U. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 2 (1985) 515-518
32. Palareti G., Legnani C., Cosmi B., Guazzaloca G., Cini M., and Mattarozzi S. Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for long-term recurrence. J Thromb Haemost 3 (2005) 955-961
33. Fihn S., McDonell M., Martin D., et al. Risk factors for complications of chronic anticoagulation. A multicenter study. Ann Intern Med 118 (1993) 511-520
34. Koopman M., Prandoni P., Piovella F., et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 334 (1996) 682-687